Quintrio
Home

PHARMACEUTICAL PREPARATIONS

AN2 Therapeutics, Inc. Common Stock

ANTX

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Last trade $4.38
Day change -$0.095 (-2.13%)
Day range $3.92 – $4.53
Volume 181,173
Market cap $170M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$169.61M
Price / earnings
—
Price / book
2.25×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.99×

Profitability

Earnings per share
-$0.92
Return on assets
-42.56%
Return on equity
-46.19%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.48×
Quick ratio
10.48×
Cash ratio
3.22×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ANTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.95M$2.89M$3.81M$2.44M$3.04M$4.02M$3.85M$3.21M
Research and development$5.72M$6.02M$6.74M$6.88M$7M$3.2M$7.69M$5.4M
Total operating expenses$8.67M$8.9M$10.55M$9.32M$10.04M$7.22M$11.54M$8.6M
Operating income-$8.67M-$8.9M-$10.55M-$9.32M-$10.04M-$7.22M-$11.54M-$8.6M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$7.96M-$8.19M-$10.03M-$8.71M-$9.35M-$6.46M-$10.65M-$7.52M
Income taxes$0$0$0$0$0$0$0$0
Net income-$7.96M-$8.19M-$10.03M-$8.71M-$9.35M-$6.46M-$10.65M-$7.52M
Net income attributable to common shareholders-$7.96M-$8.19M-$10.03M-$8.71M-$9.35M-$6.46M-$10.65M-$7.52M
EBITDA-$8.67M-$8.9M-$10.55M-$9.32M-$10.04M-$7.22M-$11.54M-$8.61M
Basic earnings per share-$0.17-$0.18-$0.29-$0.29-$0.31-$0.21-$0.35-$0.25
Diluted earnings per share-$0.17-$0.18-$0.29-$0.29-$0.31-$0.21-$0.35-$0.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight

The nontuberculous mycobacterial (NTM) infections market is projected to grow at a CAGR of 12.6% from 2026-2036, valued at USD 750 million in 2025. Growth is driven by rising disease prevalence, improved diagnostics, and emerging therapies including Omadacycline (NUZYRA), MRX-5, Epetraborole, and RHB-204. The US represents the largest market with approximately 400,000 diagnosed NTM cases across the 7MM countries.

Zacks Investment Research

Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround

AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Benzinga

ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ: MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.com shares dipped 10.1% to close at $212.01 on Monday. See how other analysts view this stock. Needham cut G1 Therapeutics, Inc. (NASDAQ: GTHX) price target from $14 to $12. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 1.1% to close at $4.48 on Monday. See how other analysts view this stock. Needham boosted the price target for Cadence Design Systems, Inc. (NASDAQ: CDNS) from $315 to $320. Needham analyst Charles Shi maintained a Buy rating. Cadence Design shares fell 1.7% to close at $306.58 on Monday. See how other analysts view this stock. B. Riley Securities cut The Children's Place, Inc. (NASDAQ:

Benzinga

Nasdaq Edges Lower; ContextLogic Shares Surge

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow traded up 0.52% to 38,873.28 while the NASDAQ fell 0.10% to 15,975.16. The S&P 500 also rose, gaining, 0.12% to 5,032.46. Check This Out: Caterpillar, Marathon Petroleum And More On CNBC's 'Final Trades'   Leading and Lagging Sectors   Energy shares rose by 1.1% on Monday. In trading on Monday, health care shares fell by 0.1%.   Top Headline   Martin Marietta Materials Inc (NYSE: MLM) disclosed a deal to acquire 20 active operations in Alabama, South Carolina, South Florida, Tennessee, and Virginia from affiliates of Blue Water Industries LLC (BWI Southeast) for $2.05 billion in cash.   Equities Trading UP   Beamr Imaging Ltd. (NASDAQ: BMR) shares shot up 1,082% to $24.96 after the company announced it will present joint research relating to automated video modernization with Nvidia at the ACM Mile-High-Video 2024 conference. Shares of ...

Benzinga

Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ: MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated video modernization with NVIDIA at the ACM Mile-High-Video 2024 conference. DIH Holdings US, Inc. (NASDAQ: DHAI) shares climbed 65.2% to $2.1306. DIH Holding US secured $1.5 million in private placement financing from OrbiMed. ContextLogic Inc. (NASDAQ: WISH) gained 40.2% to $6.31 after the company announced an agreement to sell substantially all of its operating assets and liabilities to Qoo10 for approximately $173 million in cash. SuperCom Ltd. (NASDAQ: SPCB) shares jumped 40% to $0.2570. SuperCom recently disclosed that it has secured a new contract with an established California services provider in the judicial sector. Intuitive Machines, Inc. (NASDAQ: LUNR) shares gained 33.3% to $6.65 after jumping around 32% on Friday. D-Wave Quantum Inc. (NYSE: QBTS) gained 31% to $1.4295. Renalytix Plc (NASDAQ: RNLX) surged 27% to $0.4842. Genasys Inc. (NASDAQ: GNSS) gained 27% to $1.98. Genasys bagged critical infrastructure project to engineer, procure and build emergency warning system for 37 dams across the island of Puerto Rico. Root, Inc. (NASDAQ: ROOT) rose 22.6% to $9.30. Syra Health Corp. (NASDAQ: SYRA) ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Apr 12, 2018$0.6563May 1, 2018recurring
Jan 11, 2018$0.6563Feb 1, 2018recurring
Oct 12, 2017$0.6563Nov 1, 2017recurring
Jul 12, 2017$0.6562Aug 1, 2017recurring
Apr 11, 2017$0.6563May 1, 2017recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.